Evidence map›Paper›PMID 40597707›Full record

ArticleBMC infectious diseases2025

A scoping review of human papillomavirus related data system in China.

Yongqiu Li, Ruixuan Wang, Jun Zhang, Ya-Ting Chen, Siyan Zhan, Yi Guo, Wei Wang

Erratum issuedAbstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yongqiu LiDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, PO Box 100147, Gainesville, FL, 32610, USA.
Ruixuan WangValue & Implementation Outcome Research Merck & Co., Inc, 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, 07065, USA.
Jun ZhangMSD R&D (China) Co., Ltd, Beijing, 110105, China.
Ya-Ting ChenValue & Implementation Outcome Research Merck & Co., Inc, 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, 07065, USA.
Siyan ZhanDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Haidian District, No.38, Xueyuan Rd, Beijing, China.
Yi GuoDepartment of Health Outcomes and Biomedical Informatics, University of Florida College of Medicine, PO Box 100147, Gainesville, FL, 32610, USA. yiguo@ufl.edu.
Wei WangValue & Implementation Outcome Research Merck & Co., Inc, 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, 07065, USA. wei.wang40@merck.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman papillomavirus (HPV) is a prevalent sexually transmitted infection associated with various diseases, including genital warts, recurrent respiratory papillomatosis (RRP), and multiple pre-cancerous diseases and cancers. HPV causes over 90% of cervical cancer cases, the sixth most common cancer among women in China. To support the national plan for accelerating cervical cancer elimination through enhanced HPV vaccination and screening rates, China requires reliable data systems to monitor and evaluate progress effectively.

methodsWe conducted a scoping review of literature from PubMed and the China National Knowledge Infrastructure databases, supplemented by government documents and news articles from the Internet, spanning April 2012 and July 2023. Our objective was to identify and summarize databases and data systems used for HPV-related real-world evidence generation in China. The identified data systems cover four primary domains: HPV vaccination, HPV screening, HPV-related cervical and non-cervical diseases, and sexual and lifestyle behaviors.

resultsOur review identified a total of 140 articles and 26 databases and data systems. These databases and data systems were categorized into the following reporting areas: HPV vaccination (n = 2), HPV screening (n = 2), HPV-related cervical and non-cervical diseases (n = 21), and sexual and lifestyle behaviors (n = 1). The Immunization Program Information Management System and the regional health care information platform in Ningbo provide HPV vaccination data, while KingMed Diagnostics and the "Two Cancers" Screening Platform track HPV screening at national level. Twenty-one systems were identified for tracking HPV-related cervical and non-cervical diseases, including head and neck cancers, penile lesions, and genital warts; however, no systems were found for anal, vulvar, or vaginal cancers, or RRP. One database, the National Human Immunodeficiency Viruses Epidemiology Database, included information on sexual and lifestyle behaviors. Pilot cities, including Yinzhou, Chengdu, Suzhou, and Lecheng, have implemented population-level data systems capable of identifying information on HPV vaccination, HPV screening, and HPV-related diseases.

conclusionsChina has made significant progress in addressing HPV-related diseases and prevention, but more integrated and comprehensive data systems are needed to effectively support research, improve interventions, and achieve national and global goals in HPV prevention and cervical cancer elimination.

Indexed as

PapillomaviridaePapillomavirus InfectionsChinaDatabases, FactualFemaleHuman Papillomavirus VirusesHumansMalePapillomavirus VaccinesUterine Cervical NeoplasmsVaccinationPapillomavirus VaccinesCervical cancerCervical screeningData systemsGenital wartsHuman papillomavirusReal-world dataSurveillanceVaccine

Identifiers

PMID40597707
PMCPMC12219318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.